Annual Shareholders' Meeting
May 19, 2015
10 a.m.
POWER TO CREATE.
# Fiscal 2014
Successful in difficult conditions

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>€12,917 million</td>
<td>+ 2%</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>€1,867 million</td>
<td>− 6%</td>
</tr>
<tr>
<td>Adjusted EBITDA margin</td>
<td>14.5%</td>
<td>− 1.2 pp*</td>
</tr>
<tr>
<td>Adjusted net income</td>
<td>€740 million</td>
<td>− 8%</td>
</tr>
<tr>
<td>Adjusted earnings per share</td>
<td>€1.59</td>
<td>− 8%</td>
</tr>
<tr>
<td>ROCE</td>
<td>12.3%</td>
<td>− 2.8 pp*</td>
</tr>
</tbody>
</table>

*percentage points
Dividend
Yield among the highest in the chemical industry

- Dividend policy aligned to continuity and reliability
- Constant dividend of €1 per share
- Attractive payout ratio* of 63% (2013: 56%)

* based on adjusted net income

in €

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.00</td>
<td>1.00</td>
</tr>
</tbody>
</table>

May 19, 2015 | Annual Shareholders' Meeting
Q1 2015
A strong start to the year

- Sales: €3,425 million (+ 7%)
- Adjusted EBITDA: €650 million (+ 40%)
- Adjusted EBITDA margin: 19% (+ 4.5 pp*)
- Outlook for 2015 raised: Slightly higher sales, adjusted EBITDA at least €2.2 billion

* percentage points
Evonik shares
Clear upward trend

January 1 – December 31, 2014 in €

January 1 – May 8, 2015 in €
Our strategy
Systematic realization

• Extend leading market positions
• Invest in innovations, and in organic and external growth
• Improve costs, processes and technology positions
• Strengthen competitiveness through market-oriented management and portfolio structure.
Investment program
Focused on Germany and Asia-Pacific

Capital expenditures in € million

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany</td>
<td>1,140</td>
<td>1,123</td>
</tr>
<tr>
<td>Other European countries</td>
<td></td>
<td></td>
</tr>
<tr>
<td>North America</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asia-Pacific</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other countries</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Capital expenditures 2014 by region

- Germany: 37%
- Asia-Pacific: 29%
- Other European countries: 12%
- Other: 13%
- North America: 9%
Growth projects
Aligned to global megatrends

Started operating in 2014/2015
Under construction/planned
Acquisition

*Hydrogen peroxide to propylene oxide
**Hydroxyl-terminated polybutadiene

This slide shows selected projects.
Innovation
A strategic success factor

• R&D expenses have risen by an average of 8% p.a. since 2009

• High number of initial patent applications

• Even more open to external partners in the future; higher presence in growth regions

VESTANAT® EP-IPMS enhances the scratch resistance of clear automotive paints
Optimizing administrative structures
Initial savings of around €40 million

Measures with the potential to cut costs by around €230 million will be implemented by year-end 2016

Approx. 400 measures by functions

- IT
- HR
- Communication
- Finance
- Other

2013 2014 2015 2016
New Group structure
Differentiated management of the businesses

Evonik Industries AG:
Strategic management holding company

Nutrition & Care
Resource Efficiency
Performance Materials

Growth
Efficiency
Evonik
A responsible company

Responsibility for the environment and society

Highly developed safety culture

Successful employee share program
POWER TO CREATE.